InvestorsHub Logo
icon url

linhdtu

07/12/13 10:51 AM

#10425 RE: KCSVEN #10411

Definitely you have a positive bias personally.

What do you make of Jazzbro point that from day one Jayzee should have concentrated on selling the shit out of V instead of feeding WS dream about quick $ with his "talks" BS.

I do agree with you that if the former pps highs are due to BO dreams then the price is not firm. Still say at 15, you could dilute with a 20%, 25% discount, a hell of a lot better condition than 6.

It all comes back to managing expectations and Jayzee failed miserably in that respect right from the beginning with his BO BS.
--
They would never have gotten 12 as everyone knows dilution meant GIA which meant $8 price range. It's likely they get a higher price last July right after approval but I think, at that point, they thought NCE decision and BO. Again, with price near 15 due to BO talks unclear what price they could get investors in knowing dilution meant GIA
--
icon url

Ajax133

07/12/13 12:30 PM

#10441 RE: KCSVEN #10411

KCSVEN: Your posts are interesting and certainly carry your POV.
I must ask you to share your thinking explaining THE CEO'S selling
into the approval? In 19 years in the business, I can't recall a
successful Mgmt Team being successful following a script that destroyed shareholder value, following pumping the stock with BO
rumors, and then selling. This Board has great resources, and is sharp on the Science. My lament is their forgiving nature toward Mgmt. I agree that execution has not been stellar, but that falls into the lap of Mgmt. What has the Board contributed ? I sit on the Board of 2 publicly traded Biotech Co's and with my fellow directors are proactive in helping the CEO create share holder value. I'm not trying to crucify Mgmt, but rather trying to point out that nothing happens for nothing. Hedge Funds hate uncertainty, and have issues with poor execution and lack of leadership. We can respectfully agree to disagree. The reason I'm still on board is that the fundamentals are quite compelling, and the price dislocation reflects the street's lack of confidence in Mgmt. Vascepa has blockbuster potential, and the PPS has nothing to do
with all the snake oil BS.